SAN DIEGO, CA, April 18 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation announced today that the Company has hired Peter Emtage, Ph.D., as its Vice President of Research & Development. Dr. Emtage most recently led the research, development and technical operations at Biomira Inc.
"We are very pleased to welcome Peter Emtage to the Stressgen team," commented Gregory M. McKee, President and Chief Executive Officer at Stressgen. "Peter's extensive experience in virology and immunology, coupled with a proven track record of building and leading research and development teams, provides us with valuable skills that will be critical in advancing our innovative, proprietary product candidate portfolio."
Peter Emtage joined Biomira in June 2005 as the Senior Director of Immunology and was promoted to Vice President, Research & Development and Technical Operations in February 2006. Prior to joining Biomira, Peter was the Director of Biology Research at Nuvelo Inc, a biotech company in southern California. During 2001 and 2002, Peter was an Instructor in Medicine at the Harvard Institutes of Health, Harvard Medical School. He has also held positions at Aventis Pasteur and the National Cancer Institute. Peter received his Ph.D. from McMaster University, Hamilton, Ontario and his Bachelor and Master of Science degrees from Guelph University, Guelph, Ontario.
Marvin I. Siegel, Ph.D., Executive Vice President of Research & Development at Stressgen, is leaving the Company.
About Stressgen Biotechnologies Corporation:
Stressgen is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol SSB.
About HspE7, Lead Product Candidate:
HspE7 is a novel CoVal(TM) fusion therapeutic vaccine for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common causes of sexually transmitted diseases in the world. An estimated 80 percent of sexually active men and women are infected by genital HPV at some point in their lives. Approximately 5.5 million new sexually transmitted HPV infections are reported in the U.S. each year. At least 20 million people in the U.S. are already infected. HPV infection can result in diseases including internal and external genital warts and precancerous conditions, such as cervical and anal dysplasia. Precancerous HPV-related conditions can progress into life- threatening diseases, including cervical, anal, and head and neck cancers.
For more information about Stressgen, please visit the Company's website located at www.stressgen.com.
This press release contains forward-looking statements regarding our corporate strategies, and development of therapeutics for the treatment of viral infections. Actual results could be materially different from those implied by these forward-looking statements due to factors over which we have limited control, including but not limited to our ability to continue as a going concern, our ability to enter into corporate partnering relationships (and the effects and terms of those relationships), our ability to raise additional funds, the outcomes from clinical trials, our ability to meet regulatory approval requirements difficulties inherent in the manufacture of commercial-grade drug supplies, and the risk that even if successfully developed, our products may not be commercially successful. Please refer to our filings with Canadian securities regulators for more information on these and other applicable risks. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
Director, Investor Relations
6055 Lusk Boulevard
San Diego, CA USA 92121
Stressgen Biotechnologies Corp.